Physician profile
Michele Reilly
NPI 1902890361
$293.62
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $26.90 · 2021: $75.08 · 2022: $15.32.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $100.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $34.69 | 2019-2021 | |
| Pfizer INC. | $29.75 | 2019 | |
| Genentech USA, INC. | $23.39 | 2021 | |
| Neos Therapeutics, LP | $22.10 | 2019 | |
| Ironshore Pharmaceuticals INC. | $21.59 | 2019 | |
| Sanofi Pasteur INC. | $18.04 | 2021 | |
| Tris Pharma INC | $16.26 | 2021 | |
| Cranial Technologies, INC | $15.70 | 2019 | |
| Kaleo, INC. | $11.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.